A5022486856- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Cancer Immunotherapy and Biomarkers
- Chromatin Remodeling and Cancer
- Liver physiology and pathology
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Tissue Engineering and Regenerative Medicine
- Ubiquitin and proteasome pathways
- Metastasis and carcinoma case studies
- TGF-β signaling in diseases
- Pancreatic and Hepatic Oncology Research
- Mechanisms of cancer metastasis
- Ferroptosis and cancer prognosis
- Vascular Malformations and Hemangiomas
Affiliated Hospital of Qingdao University
2016-2025
Qingdao University
2016-2025
First Affiliated Hospital of Harbin Medical University
2025
Queen Mary Hospital
2025
Guangzhou Eighth People's Hospital
2024
Guangzhou Medical University
2024
Gansu University of Traditional Chinese Medicine
2024
Inner Mongolia University
2024
State Key Laboratory of Oncogene and Related Genes
2012-2018
Renji Hospital
2012-2018
IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun be used China. It provides physicians with evidence-based treatment options ranks them three categories decision support. This study was designed examine the concordance between recommendation proposed by WFO actual clinical decisions oncologists our cancer center, would reflect differences of China U.S.Retrospective from 362 patients were ingested into...
CD133+ cancer stem cells (CSC) contribute to hepatocellular carcinoma (HCC) progression and resistance therapy. Bone morphogenetic protein BMP4 plays an important role in hepatogenesis hepatic cell differentiation, but little is known about its function CSCs. In this study, we showed that high-dose exogenous promotes HCC CSC differentiation inhibits the self-renewal, chemotherapeutic resistance, tumorigenic capacity of these cells. Interestingly, found low-dose upregulated CD133 expression...
Background: A total of 2%–7% non-small cell lung cancer (NSCLC) patients have anaplastic lymphoma kinase (ALK) mutations. At present, three or more generations ALK inhibitors been used for ALK-positive NSCLC treatment, including crizotinib, alectinib, ceritinib, and brigatinib. Although most adverse events (AEs) are grades 1 to 2 generally can be well tolerated, serious (SAEs) lack data analysis, the toxicity needs attention. Thus, we performed this meta-analysis evaluate safety inhibitors,...
Patients with advanced non-small cell lung cancer (NSCLC) benefit from treatment immune checkpoint inhibitors (ICIs). Biomarkers such as programmed death-ligand 1 (PD-L1), the tumor mutational burden (TMB) and mismatch repair (MMR) status are used to predict prognosis of ICIs therapy. Nevertheless, novel biomarkers need be further investigated, a systematic prognostic model is needed for evaluation survival risks treatment.A cohort 240 patients who received cBioPortal Cancer Genomics was...
Ribonucleotide reductase (RR)M2B is an enzyme belonging to the ribonucleotide family, which essential for DNA synthesis and repair. RRM2B plays important role in tumor progression metastasis; however, little known about expression underlying molecular mechanisms of hepatocellular carcinoma (HCC). In present study, we report that down-regulation HCC negatively associated with intrahepatic metastasis, regardless p53 status. Moreover, ectopic overexpression decreased cell migration invasion...
The treatment of human hepatocellular carcinoma (HCC) cell lines with (+)-isocorydine, which was isolated and purified from Papaveraceae sp. plants, resulted in a growth inhibitory effect caused by the induction G2/M phase cycle arrest apoptosis. We report that isocorydine induces increasing cyclin B1 p-CDK1 expression levels, decreasing inhibiting activation Cdc25C. phosphorylation levels Chk1 Chk2 were increased after ICD treatment. Furthermore, induced can be disrupted siRNA but not...
Isocorydine (ICD), an anticancer agent under current evaluation, decreased the percentage of side population (SP) cells significantly in hepatocellular carcinoma (HCC) cell lines. ICD treatment sensitized cancer to doxorubicin (DXR), a conventional clinical chemotherapeutic drug for HCC. We found that SP HCC lines by preferentially killing cells. In early stage treatment, inhibited growth arresting G2/M; later, it induced apoptosis. Our xenograft model confirmed selectively reduced size and...
// Lin Zhang 1,* , Hong Li Chao Ge 1 Meng Fang-yu Zhao He-lei Hou Miao-xin Zhu Hua Tian Li-xing Tao-yang Chen 2 Guo-ping Jiang 3 Hai-yang Xie Ying Cui 4 Ming Yao and Jin-jun State Key Laboratory of Oncogenes Related Genes, Shanghai Cancer Institute, Renji Hospital, Jiaotong University School Medicine, Shanghai, China Qi Dong Liver Dong, Department General Surgery, the First Affiliated Zhejiang University, Hangzhou, Institute Guangxi, Nanning, * These authors contributed equally to this work...
Abstract Background Occurrence at a younger age has been demonstrated to be associated with distinct biology in non-small cell lung cancer. However, genomics and clinical characteristics among patients adenocarcinoma remain determined. Here we studied the potentially targetable genetic alterations by next-generation sequencing (NGS) assay young Chinese adenocarcinoma. Materials Methods Seventy-one surgically resected tissue samples from aged less than 45 years were collected informed consent...
PD-1 blockade has been shown to have promising efficacy and acceptable safety profiles in advanced metastatic gastric cancer; however, the of neoadjuvant blockade-based immunotherapy plus chemotherapy locally cancer (LAGC) remain uncertain. We performed a retrospective review patients with LAGC who received treatment followed by D2 radical resection at Affiliated Hospital Qingdao University from 2019 2021. The primary aim was investigate difference pathological response rates between alone....
Limited treatment options exist for refractory ovarian cancer (OC) due to its poor response immune therapies. Therefore, there is an urgent need develop new effective strategies. Chicoric acid (CA) reported have immune-enhancing properties, but efficacy in not well understood. We hypothesize that CA might improve the of PD-1/PD-L1 blockade immunotherapy OC patients. Patient-derived xenograft (PDX) models were constructed from chemoresistant advanced high-grade serous These treated with CA,...
// Na Zhou 1 , Congmin Liu 2 Helei Hou Chuantao Zhang Dong Guanqun Wang 3 Kewei Jingjuan Zhu Hongying Lv Tianjun Li and Xiaochun Department of Oncology, The Affiliated Hospital Qingdao University, Qingdao, China Municipal Hospital, Pathology, Correspondence to: Zhang, email: Keywords : spindle cell carcinoma; Apatinib; VEGFR; targeted therapy Received July 04, 2016 Accepted October 03, Published 11, Abstract Spindle carcinoma the breast is a rare subtype metaplastic carcinoma, no effective...
Background Serous ovarian carcinoma (SOC) is the most lethal subtype of cancer, with chemoresistance to platinum-based chemotherapy remaining a major challenge in improving clinical outcomes. The role tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), modulating responses not yet fully understood. Methods To explore relationship between CAF subtypes and sensitivity, we employed single-cell RNA sequencing (scRNA-seq), bulk RNA-seq, spatial transcriptomics,...